Source: MarketScreener

Eli Lilly: Eli Lilly and : Lilly to Participate in Guggenheim Biopharma Strategy Series

(marketscreener.com) INDIANAPOLIS, June 14, 2021 /PRNewswire/ -- Eli Lilly and Company will participate in the Guggenheim Biopharma Strategy Series - Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation - on Friday, June 18, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific and Medical Officer and President of...https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-and-nbsp-Lilly-to-Participate-in-Guggenheim-Biopharma-Strategy-Series-35600575/?utm_medium=RSS&utm_content=20210614

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
$25.5B
Employees
38,680
David A. Ricks's photo - Chairman & CEO of Eli Lilly

Chairman & CEO

David A. Ricks

CEO Approval Rating

65/100

Read more